Relevium Medical GTM brain

category

market profile

• text: Knee osteoarthritis causes chronic progressive pain for which existing treatments can leave unmet needs.
• text: RM-010 is a development-stage candidate, with clinical validation and regulatory review central to any eventual commercial adoption.

personas

• title: Orthopedic or musculoskeletal pain specialist
  pains:

  • Patients with persistent knee pain may receive repeat injections or systemic medication
  • Needs strong human evidence, safety data and a practical in-office workflow before adoption
• title: Pharma business development or medical affairs leader
  pains:

  • Needs differentiated non-opioid pain assets with a credible development pathway
  • Must assess trial design, regulatory risk and rights before partnering
• title: Health plan medical director
  pains:

  • Must judge clinical benefit and total care costs against established injection therapies
  • Needs evidence and reimbursement terms before considering coverage

icp

• text: Potential future prescribers include orthopedic and pain clinics treating knee osteoarthritis; availability depends on clinical development and approval.
• text: Potential development partners include biopharma companies with pain or musculoskeletal portfolios and clinical trial capabilities.

message pillars

• text: Focus on chronic pain and urologic disorders.
• text: Develop patient-focused therapies where current treatments fall short.
• text: Target peripheral nervous system hyperexcitability through TRPV1.

objections

• objection: Is the treatment proven in patients?
  response: The candidate is investigational; share current trial status and data without presenting preclinical results as proven patient outcomes.
• objection: How does it compare with standard injections?
  response: Discuss available comparative data and study design; avoid assuming superiority before adequate clinical trials.
• objection: Will insurers reimburse it?
  response: Coverage and pricing are unknown pending development and regulatory outcomes.

competitors

• name: Seikagaku Corporation
  why: Markets Gel-One, an intra-articular knee osteoarthritis treatment.
• name: Levicept
  why: Develops an investigational osteoarthritis pain treatment.

keywords

• knee osteoarthritis injectable therapy
• non opioid osteoarthritis pain treatment
• TRPV1 osteoarthritis drug
• long acting knee pain injection
• osteoarthritis clinical trial
• intra articular pain therapy

voice

• clinical
• patient-focused
• research-led

signals

• text: A clinic participates in knee osteoarthritis or pain trials and seeks investigational non-opioid therapies.
• text: A pharmaceutical partner seeks local pain assets in development.

pricing

motion

channels

• clinical research partnerships
• press

confidence

Founders

• name: Alison Liddy
  title: Founder
  role: Founder
  bio: Alison is CEO and Founder at Relevium Medical. Alison holds qualifications in Chemistry and Biochemical Engineering (M.Sc. & Ph.D.). She has worked for major multinational companies including ROCHE, Cook Medical and Boston Scientific; and completed the BioInnovate Fellowship in the prestigious Stanford BioDesign-affiliated program at NUI Galway, Ireland. She is the named inventor on over 20 patent publications and the winner of the Science Foundation of Ireland’s €1 million innovation prize.